The β-blocker Nebivolol Is a GRK/β-arrestin Biased Agonist

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Erickson, Catherine E ^a,b   Gul, Rukhsana ^a,b,c   Blessing, Christopher P ^a   Nguyen, Jenny ^f   Liu, Tammy ^f   Pulakat, Lakshmi ^a,b   Bastepe, Murat ^d   Jackson, Edwin K ^e   Andresen, Bradley T ^a,f  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; MITOGEN ACTIVATED PROTEIN KINASE; NEBIVOLOL;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; ENZYME INHIBITION; INTERNALIZATION; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANIMALS; ARRESTINS; BENZOPYRANS; CARBAZOLES; CELL LINE; ETHANOLAMINES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; G-PROTEIN-COUPLED RECEPTOR KINASE 2; MAP KINASE SIGNALING SYSTEM; MICE; NITRIC OXIDE; PHOSPHORYLATION; PROPANOLAMINES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ADRENERGIC, BETA-2;

EID: 84882629555     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071980     Document Type: Article

References (51)

1. Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J, et al. (1988) Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol 11: 552-563.
2. Brixius K, Bundkirchen A, Bolck B, Mehlhorn U, Schwinger RH, (2001) Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol 133: 1330-1338.
3. Bowman AJ, Chen CP, Ford GA, (1994) Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 38: 199-204.
4. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, et al. (1995) Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 274: 1067-1071.
5. Feng MG, Prieto MC, Navar LG (2012) Nebivolol induced vasodilation of renal afferent arterioles involves beta3 adrenergic receptor and nitric oxide synthase activation. Am J Physiol Renal Physiol.
6. de Groot AA, Mathy MJ, van Zwieten PA, Peters SL, (2003) Involvement of the beta3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta. J Cardiovasc Pharmacol 42: 232-236.
7. Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva II, et al. (2005) Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 112: 1198-1205.
8. Gosgnach W, Boixel C, Nevo N, Poiraud T, Michel JB, (2001) Nebivolol induces calcium-independent signaling in endothelial cells by a possible beta-adrenergic pathway. J Cardiovasc Pharmacol 38: 191-199.
9. Frazier EP, Michel-Reher MB, van Loenen P, Sand C, Schneider T, et al. (2011) Lack of evidence that nebivolol is a beta-adrenoceptor agonist. EurJPharmacol 654: 86-91.
10. Pauwels PJ, Gommeren W, Van Lommen G, Janssen PA, Leysen JE, (1988) The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers. Mol Pharmacol 34: 843-851.
11. Veverka A, Salinas JL, (2007) Nebivolol in the treatment of chronic heart failure. Vasc Health Risk Manag 3: 647-654.
12. Broeders MA, Doevendans PA, Bekkers BC, Bronsaer R, van Gorsel E, et al. (2000) Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation 102: 677-684.
13. Pauwels PJ, Leysen JE, Janssen PA, (1989) Beta-adrenoceptor-mediated cAMP accumulation in cardiac cells: effects of nebivolol. Eur J Pharmacol 172: 471-479.
14. Pauwels PJ, Van Gompel P, Leysen JE, (1991) Human beta 1- and beta 2-adrenergic receptor binding and mediated accumulation of cAMP in transfected Chinese hamster ovary cells. Profile of nebivolol and known beta-adrenergic blockers. Biochem Pharmacol 42: 1683-1689.
15. Andresen BT, (2011) A pharmacological primer of biased agonism. EndocrMetab ImmuneDisordDrug Targets 11: 92-98.
16. Lefkowitz RJ, Shenoy SK, (2005) Transduction of receptor signals by beta-arrestins. Science 308: 512-517.
17. Shenoy SK, Lefkowitz RJ, (2003) Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem J 375: 503-515.
18. Dinicolantonio JJ, Hackam DG, (2012) Carvedilol: a third-generation beta-blocker should be a first-choice beta-blocker. Expert Rev Cardiovasc Ther 10: 13-25.
19. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, et al. (2007) A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. ProcNatlAcadSciUSA 104: 16657-16662.
20. Kim IM, Tilley DG, Chen J, Salazar NC, Whalen EJ, et al. (2008) Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A 105: 14555-14560.
21. Tzingounis AV, von Zastrow M, Yudowski GA, (2010) {Beta}-blocker drugs mediate calcium signaling in native central nervous system neurons by {beta}-arrestin-biased agonism. Proc Natl Acad Sci U S A 107: 21028-21033.
22. Afonso RA, Patarrao RS, Macedo MP, Carmo MM, (2006) Carvedilol action is dependent on endogenous production of nitric oxide. AmJHypertens 19: 419-425.
23. Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, et al. (2007) Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. JClinInvest 117: 2445-2458.
24. Mehta VB, Zhou Y, Radulescu A, Besner GE, (2008) HB-EGF stimulates eNOS expression and nitric oxide production and promotes eNOS dependent angiogenesis. Growth Factors 26: 301-315.
25. Namiki A, Akatsuka N, (1990) Vascular smooth muscle relaxation induced by epidermal growth factor is endothelium-dependent. EurJPharmacol 180: 247-254.
26. Zhou Y, Brigstock D, Besner GE, (2009) Heparin-binding EGF-like growth factor is a potent dilator of terminal mesenteric arterioles. MicrovascRes 78: 78-85.
27. Hamdani N, van der Velden J, (2009) Lack of specificity of antibodies directed against human beta-adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 379: 403-407.
28. Bastepe M, Gunes Y, Perez-Villamil B, Hunzelman J, Weinstein LS, et al. (2002) Receptor-mediated adenylyl cyclase activation through XLalpha(s), the extra-large variant of the stimulatory G protein alpha-subunit. Mol Endocrinol 16: 1912-1919.
29. Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, et al. (1998) HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A 95: 2979-2984.
30. Andresen BT, (2010) Characterization of G protein-coupled receptor kinase 4 and measuring its constitutive activity in vivo. Methods Enzymol 484: 631-651.
31. Ren J, Mi Z, Jackson EK, (2008) Assessment of nerve stimulation-induced release of purines from mouse kidneys by tandem mass spectrometry. JPharmacolExpTher 325: 920-926.
32. Seibold A, January BG, Friedman J, Hipkin RW, Clark RB, (1998) Desensitization of beta2-adrenergic receptors with mutations of the proposed G protein-coupled receptor kinase phosphorylation sites. Journal of Biological Chemistry 273: 7637-7642.
33. Staehelin M, Simons P, Jaeggi K, Wigger N, (1983) CGP-12177. A hydrophilic beta-adrenergic receptor radioligand reveals high affinity binding of agonists to intact cells. Journal of Biological Chemistry 258: 3496-3502.
34. Escano CS Jr, Keever LB, Gutweiler AA, Andresen BT, (2008) Angiotensin II activates extracellular signal-regulated kinase independently of receptor tyrosine kinases in renal smooth muscle cells: implications for blood pressure regulation. JPharmacolExpTher 324: 34-42.
35. Rautureau Y, Toumaniantz G, Serpillon S, Jourdon P, Trochu JN, et al. (2002) Beta 3-adrenoceptor in rat aorta: molecular and biochemical characterization and signalling pathway. Br J Pharmacol 137: 153-161.
36. Matsushita M, Tanaka Y, Koike K, (2006) Studies on the mechanisms underlying beta-adrenoceptor-mediated relaxation of rat abdominal aorta. J Smooth Muscle Res 42: 217-225.
37. Lonnqvist F, Krief S, Strosberg AD, Nyberg S, Emorine LJ, et al. (1993) Evidence for a functional beta 3-adrenoceptor in man. Br J Pharmacol 110: 929-936.
38. Niclauss N, Michel-Reher MB, Alewijnse AE, Michel MC, (2006) Comparison of three radioligands for the labelling of human beta-adrenoceptor subtypes. Naunyn Schmiedebergs ArchPharmacol 374: 99-105.
39. Thompson JE, Venegas FD, Raines RT, (1994) Energetics of catalysis by ribonucleases: fate of the 2',3'-cyclic phosphodiester intermediate. Biochemistry 33: 7408-7414.
40. Garbin U, Pasini AF, Stranieri C, Manfro S, Boccioletti V, et al. (2007) Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity. Pharmacol Res 56: 515-521.
41. Ye H, Ling S, Castillo AC, Thomas B, Long B, et al. (2013) Nebivolol Induces Distinct Changes in Profibrosis MicroRNA Expression Compared With Atenolol, in Salt-Sensitive Hypertensive Rats. Hypertension 61: 1008-1013.
42. Ruffolo RR Jr, Gellai M, Hieble JP, Willette RN, Nichols AJ, (1990) The pharmacology of carvedilol. Eur J Clin Pharmacol 38Suppl 2: S82-88.
43. Iino M, Furugori T, Mori T, Moriyama S, Fukuzawa A, et al. (2002) Rational design and evaluation of new lead compound structures for selective betaARK1 inhibitors. J Med Chem 45: 2150-2159.
44. Rajagopal S, Rajagopal K, Lefkowitz RJ, (2010) Teaching old receptors new tricks: biasing seven-transmembrane receptors. NatRevDrug Discov 9: 373-386.
45. Price A, Raheja P, Wang Z, Arbique D, Adams-Huet B, et al. (2013) Differential effects of nebivolol versus metoprolol on functional sympatholysis in hypertensive humans. Hypertension 61: 1263-1269.
46. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, et al. (1999) EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402: 884-888.
47. Pierce KL, Tohgo A, Ahn S, Field ME, Luttrell LM, et al. (2001) Epidermal growth factor (EGF) receptor-dependent ERK activation by G protein-coupled receptors: a co-culture system for identifying intermediates upstream and downstream of heparin-binding EGF shedding. Journal of Biological Chemistry 276: 23155-23160.
48. Xiao K, Sun J, Kim J, Rajagopal S, Zhai B,et al. (2010) Global phosphorylation analysis of {beta}-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). ProcNatlAcadSciUSA.
49. Christensen GL, Kelstrup CD, Lyngso C, Sarwar U, Bogebo R, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. MolCell Proteomics 9: 1540-1553.
50. Tilley DG, (2011) G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function. Circ Res 109: 217-230.
51. Rakesh K, Yoo B, Kim IM, Salazar N, Kim KS, et al. (2010) beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. SciSignal 3: ra46.